Search
Triclabendazole
go.drugbank.com/drugs/DB12245ApprovedInvestigationalTriclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. … [FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 SubstratesApadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … [A262076] Patients with cTTP have a severe deficiency of a plasma metalloproteinase called ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible
Synonyms: Recombinant disintegrin and metalloprotease with thrombospondin type 1 motifsMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Synonyms: Vitamin K 3, 2-Methyl-1,4-naphthochinonMixtures: LIBAVIT-K 20 MG AMPUL, 5 ADETXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLinerixibat
go.drugbank.com/drugs/DB11729ApprovedInvestigationalLinerixibat is a first-in-class and small-molecule inhibitor of the ileal bile acid transporter (IBAT). … [A275481, A275482] On March 19, 2026, linerixibat was approved by the FDA for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Categories: Cytochrome P-450 CYP3A Inhibitors, Heterocyclic Compounds, 1-RingSynonyms: 3-((((3R,5R)-3-BUTYL-3-ETHYL-7-METHOXY-1,1-DIOXO-5-PHENYL-2,3,4,5-TETRAHYDRO- 1H-1.LAMBDA.6,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)PENTANEDIOIC ACID, PENTANEDIOIC ACID, 3-((((3R,5R)-3-BUTYL-3-ETHYL-2,3,4,5-TETRAHYDRO-7-METHOXY-1,1-DIOXIDO-5-PHENYL-1,4-BENZOTHIAZEPIN-8-YL)METHYL)AMINO)-Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a 32 amino acid recombinant human B-type natriuretic peptide. … Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).
Categories: Vasodilators Used in Cardiac DiseasesNickel sulfate
go.drugbank.com/drugs/DB14180ApprovedNickel sulfate is used in allergenic testing.
Synonyms: nickel(II) sulfate, Nickel sulfate(1:1)Categories: Compounds used in a research, industrial, or household settingMethylnaltrexone
go.drugbank.com/drugs/DB06800ApprovedInvestigationalIt is also a weak CYP2D6 inhibitor. FDA approved in 2008. … Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms.
Categories: Heterocyclic Compounds with 4 or More RingsZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalZavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally. … [L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways.
Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-Categories: MATE 1 Substrates, P-glycoprotein substratesMotixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[L48136] Similar in mechanism to the previously approved [plerixafor], motixafortide is an inhibitor of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow … [A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple